{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:16:36Z","timestamp":1788405396649,"version":"build-2803163510"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Massachusetts General Hospital Fracture Liaison Service"},{"name":"Department of Orthopedics, Department of Medicine"},{"name":"MGH Care Redesign Initiative program"},{"name":"Clinical Impact Research Award"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Zoledronic acid (ZA), cleared renally, carries a higher nephrotoxicity risk at doses \u22654\u00a0mg, especially in patients with CKD. While 5\u00a0mg is standard for osteoporosis, ZA increases BMD at doses as low as 0.25\u00a0mg every 3\u00a0mo. Inpatient ZA (IP-ZA) in hip fracture patients reduces mortality and re-fracture risk, but its safety in those with advanced CKD (creatinine clearance rate (CrCl)\u2009&amp;lt;\u200935\u00a0mL\/min) is unclear. We analyzed real-world data from a large academic healthcare system to assess the safety of reduced-dose IP-ZA (\u22643\u00a0mg) in hip fracture patients with advanced CKD, compared to propensity-matched controls receiving no anti-osteoporosis medication during index hip fracture hospitalization. The study included 328 IP-ZA patients and 2308 controls, with a primary cohort of 46 IP-ZA patients and 98 matched untreated controls, predominantly female (77.8%), White (92.4%), with a mean age of 89.9\u00a0yr and CrCl of 31.1\u2009\u00b1\u20090.6\u00a0mL\/min. The IP-ZA group received an average dose of 2.7\u2009\u00b1\u20090.1\u00a0mg (1 patient at 1\u00a0mg, 11 at 2\u00a0mg, 34 at 3\u00a0mg) on postoperative day 2.9\u2009\u00b1\u20090.3. All patients received standing acetaminophen, calcium (650-1000\u00a0mg\/d), and vitamin D (1000-2500\u00a0IU\/d) post-surgery. We monitored daily maximum body temperature, serum creatinine, and serum calcium for 5\u00a0d, starting the day before IP-ZA administration (or postoperative day 2 for controls). Inpatient-ZA did not affect temperature, with new-onset fever (\u226538.0\u00a0\u00b0C, days 2-4) in 1 IP-ZA patient and 2 controls. Serum creatinine level remained stable. Serum calcium level in the IP-ZA group decreased from 8.8\u2009\u00b1\u20090.1 to 8.2\u2009\u00b1\u20090.2\u00a0mg\/dL by day 5, unchanged in controls; no IP-ZA patient had serum calcium level &amp;lt;7.5\u00a0mg\/dL. Hospital length-of-stay (6.2\u2009\u00b1\u20090.4 vs 6.5\u2009\u00b1\u20090.4\u00a0d, p\u2009=\u2009.41) and 30-d readmission rates were similar. This study suggests that reduced-dose IP-ZA is likely safe for patients with hip fracture and advanced CKD who are otherwise at high risk for being untreated.<\/jats:p>","DOI":"10.1093\/jbmr\/zjaf195","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:57:46Z","timestamp":1765976266000},"page":"710-716","source":"Crossref","is-referenced-by-count":3,"title":["Safety of low dose inpatient zoledronic acid in acute hip fracture patients with advanced chronic kidney disease"],"prefix":"10.1093","volume":"41","author":[{"given":"Xiaoxu","family":"Sun","sequence":"first","affiliation":[{"name":"Division of Endocrine, Massachusetts General Hospital , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2051-0505","authenticated-orcid":false,"given":"Benjamin Z","family":"Leder","sequence":"additional","affiliation":[{"name":"Division of Endocrine, Massachusetts General Hospital , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuan V","family":"Ly","sequence":"additional","affiliation":[{"name":"Harvard Orthopaedic Trauma Initiative, Massachusetts General Hospital , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Franco-Garcia","sequence":"additional","affiliation":[{"name":"Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcy B","family":"Bolster","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Massachusetts General Hospital , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5081-4809","authenticated-orcid":false,"given":"WuQiang","family":"Fan","sequence":"additional","affiliation":[{"name":"Division of Endocrine, Massachusetts General Hospital , Boston, MA 02114 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"issue":"1","key":"2026081703264440800_ref1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1210\/clinem\/dgac508","article-title":"Inpatient zoledronic acid and integrated orthopedic and fracture liaison services improve osteoporosis treatment rates","volume":"108","author":"Fan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026081703264440800_ref2","doi-asserted-by":"crossref","first-page":"e1282","DOI":"10.1210\/clinem\/dgad295","article-title":"Safety of inpatient zoledronic acid in the immediate postfracture setting","volume":"108","author":"Fan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026081703264440800_ref3","first-page":"1061","article-title":"Zoledronic acid for hip fracture during initial hospitalization","volume":"39","author":"Fan","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2026081703264440800_ref4","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"issue":"17","key":"2026081703264440800_ref5","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"2026081703264440800_ref6","doi-asserted-by":"crossref","first-page":"e240159","DOI":"10.20945\/2359-4292-2024-0159","article-title":"Single zoledronic acid infusion as a cause of acute kidney impairment requiring dialysis in two patients with osteoporosis","volume":"v.68","author":"Marina","year":"2024","journal-title":"Arch Endocrinol Metab"},{"issue":"18","key":"2026081703264440800_ref7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"18","key":"2026081703264440800_ref8","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"issue":"18","key":"2026081703264440800_ref9","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","article-title":"Fracture risk and zoledronic acid therapy in men with osteoporosis","volume":"367","author":"Boonen","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2026081703264440800_ref10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"2026081703264440800_ref11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson comorbidity index: a critical review of clinimetric properties","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother Psychosom"},{"issue":"8","key":"2026081703264440800_ref12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"9","key":"2026081703264440800_ref13","doi-asserted-by":"crossref","first-page":"e2336023","DOI":"10.1001\/jamanetworkopen.2023.36023","article-title":"Reporting of observational studies explicitly aiming to emulate randomized trials: a systematic review","volume":"6","author":"Hansford","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"2026081703264440800_ref14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1037\/a0019623","article-title":"Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research","volume":"15","author":"Harder","year":"2010","journal-title":"Psychol Methods"},{"issue":"5","key":"2026081703264440800_ref15","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/aje\/kwp425","article-title":"Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation","volume":"171","author":"Lee","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"3","key":"2026081703264440800_ref16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0962280206074463","article-title":"Multiple imputation of discrete and continuous data by fully conditional specification","volume":"16","author":"van Buuren","year":"2007","journal-title":"Stat Methods Med Res"},{"issue":"9","key":"2026081703264440800_ref17","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/jbmr.2301","article-title":"The osteoporosis treatment gap","volume":"29","author":"Kanis","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2026081703264440800_ref18","doi-asserted-by":"crossref","first-page":"bvae050","DOI":"10.1210\/jendso\/bvae050","article-title":"A fracture liaison service to address vitamin D deficiency for patients hospitalized for osteoporotic fracture","volume":"8","author":"Sun","year":"2024","journal-title":"J Endocr Soc"},{"issue":"1","key":"2026081703264440800_ref19","first-page":"1","article-title":"KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and bone Disorder (CKD-MBD)","volume":"7","author":"Kidney Disease: Improving Global Outcomes CKDMBDUWG","year":"2017","journal-title":"Kidney Int Suppl (2011)"},{"issue":"9","key":"2026081703264440800_ref20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/M16-2752","article-title":"Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"166","author":"Wilson","year":"2017","journal-title":"Ann Intern Med"},{"issue":"7","key":"2026081703264440800_ref21","first-page":"CD013424","article-title":"Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D","volume":"7","author":"Hara","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2026081703264440800_ref22","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2026081703264440800_ref23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2023.28239","article-title":"Severe Hypocalcemia with denosumab among older female dialysis-dependent patients","volume":"331","author":"Bird","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"2026081703264440800_ref24","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"Chen","year":"2002","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"2026081703264440800_ref25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00774-016-0806-3","article-title":"Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis","volume":"35","author":"Shiraki","year":"2017","journal-title":"J Bone Miner Metab"},{"issue":"1","key":"2026081703264440800_ref26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"issue":"1","key":"2026081703264440800_ref27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jbmr.3877","article-title":"Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition","volume":"35","author":"Conley","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026081703264440800_ref28","doi-asserted-by":"crossref","first-page":"e2455251","DOI":"10.1001\/jamanetworkopen.2024.55251","article-title":"Use of albumin-adjusted calcium measurements in clinical practice","volume":"8","author":"Desgagnes","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2026081703264440800_ref29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1359\/jbmr.2003.18.4.591","article-title":"How well are bones designed to resist fracture?","volume":"18","author":"Currey","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2026081703264440800_ref30","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1359\/jbmr.1998.13.8.1337","article-title":"The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong osteoporosis study","volume":"13","author":"Sanders","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2026081703264440800_ref31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1759720X16650866","article-title":"Intravenous zoledronate for osteoporosis: less might be more","volume":"8","author":"Grey","year":"2016","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"2026081703264440800_ref32","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1210\/jc.2011-2081","article-title":"Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial","volume":"97","author":"Grey","year":"2012","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjaf195\/66281748\/zjaf195.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/7\/710\/66281748\/zjaf195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/7\/710\/66281748\/zjaf195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T07:26:50Z","timestamp":1786951610000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/41\/7\/710\/8415516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,1,6]]},"published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjaf195","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,1,6]]}}}